5th May 2015 07:44
LONDON (Alliance News) - Oxford BioMedica PLC said Tuesday said data from an ongoing follow-up study of its Parkinson's disease treatment ProSavin is "very encouraging", as results from its phase I study of wet age-related macular degeneration was picked as a 'hot topic' at a recent conference.
The results from a year and three-year follow-up of the ProSavin study were presented at the American Association of Neurological Surgeons conference on Monday. The data, which has been previously announced, showed that ProSavin met its endpoint of safety and tolerability at all dose levels.
Separately at the Association for Research in Vision and Opthalmology conference on Monday, Oxford BioMedica's results from the RetinoStat study were presented via poster. The annual meeting programme committee of the conference selected the poster due to it "representing the newest and most innovative research being conducted in ophthalmology", the company said.
The study met its six month primary endpoints of safety and tolerability. Data from the study is due to be published in a peer reviewed journal in "due course."
Oxford Biomedica shares are trading up 3.7% at 11.67 pence Tuesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Biomedica